Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection
Image credit: American Society of Nephrology
Abstract
The effects of dapagliflozin on primary and secondary outcomes in hospitalized participants with COVID-19 were consistent in those with eGFR below/above 60 ml/min per 1.73 m2. Dapagliflozin was well tolerated and did not increase the risk of AKI in participants with eGFR below or above 60 ml/min per 1.73 m2.
- Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection was published in Clinical Journal of the American Society of Nephrology 17, no. 5 (2022): 643-654
Type
